Research location

Collierville

Tennessee, United States

Published trials94

Site observations96

Linked trials published94

Page1 / 2

Research activity in Collierville

Tennessee, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 94 trials and 96 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Collierville

94 linked trials · page 1 of 2

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After TreatmentNCT07293247 · 2026-10-14 · 1 site observation

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialNCT07391774 · 2026-08-10 · 1 site observation

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280 · 2025-09-29 · 1 site observation

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabNCT06876714 · 2025-09-17 · 1 site observation

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)NCT06616584 · 2025-05-22 · 1 site observation

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialNCT06498635 · 2025-04-01 · 1 site observation

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology ClinicsNCT06418204 · 2025-01-30 · 1 site observation

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)NCT06116682 · 2024-11-19 · 1 site observation

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)NCT06031688 · 2024-08-08 · 1 site observation

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerNCT06058377 · 2023-11-27 · 1 site observation

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 1 site observation

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerNCT05929768 · 2023-09-15 · 1 site observation

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerNCT05624996 · 2023-07-12 · 1 site observation

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 1 site observation

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)NCT05642572 · 2023-05-05 · 1 site observation

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07 · 1 site observation

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · 2020-12-28 · 1 site observation

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 1 site observation

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerNCT03851445 · 2019-02-06 · 1 site observation

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerNCT03723928 · 2018-09-17 · 1 site observation

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityNCT03418961 · 2017-11-01 · 1 site observation

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung CancerNCT06732401 · 2025-08-07 · 1 site observation

ACTIVE_NOT_RECRUITING

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung CancerNCT06632327 · 2024-12-11 · 1 site observation

ACTIVE_NOT_RECRUITING

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC PatientsNCT06538038 · 2024-09-17 · 1 site observation

ACTIVE_NOT_RECRUITING

Mobile Health for Adherence in Breast Cancer PatientsNCT06112613 · 2024-04-02 · 1 site observation

ACTIVE_NOT_RECRUITING

Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE TrialNCT06216574 · 2024-03-14 · 1 site observation

ACTIVE_NOT_RECRUITING

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer SurvivorsNCT05896189 · 2024-02-29 · 1 site observation

ACTIVE_NOT_RECRUITING

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast CancerNCT05705401 · 2023-05-19 · 1 site observation

ACTIVE_NOT_RECRUITING

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT TrialNCT05710328 · 2023-05-10 · 1 site observation

ACTIVE_NOT_RECRUITING

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudyNCT05633602 · 2023-03-14 · 1 site observation

ACTIVE_NOT_RECRUITING

Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung CancerNCT05364645 · 2022-07-25 · 1 site observation

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung CancerNCT04989283 · 2021-09-09 · 1 site observation

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain MetastasesNCT04647916 · 2021-06-08 · 1 site observation

ACTIVE_NOT_RECRUITING

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT04625647 · 2021-04-16 · 1 site observation

ACTIVE_NOT_RECRUITING

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · 2021-03-02 · 1 site observation

ACTIVE_NOT_RECRUITING

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer PatientsNCT04310020 · 2021-01-13 · 1 site observation

ACTIVE_NOT_RECRUITING

Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)NCT04496739 · 2020-10-23 · 1 site observation

ACTIVE_NOT_RECRUITING

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung CancerNCT04214262 · 2020-08-13 · 1 site observation

ACTIVE_NOT_RECRUITING

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive BiomarkerNCT04334941 · 2020-07-20 · 1 site observation

ACTIVE_NOT_RECRUITING

NCI COVID-19 in Cancer Patients, NCCAPS StudyNCT04387656 · 2020-06-05 · 1 site observation

ACTIVE_NOT_RECRUITING

S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung CancerNCT04155034 · 2020-05-04 · 1 site observation

ACTIVE_NOT_RECRUITING

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerNCT04092283 · 2020-04-29 · 1 site observation

ACTIVE_NOT_RECRUITING

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyNCT04266249 · 2020-03-13 · 1 site observation

ACTIVE_NOT_RECRUITING

Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast CancerNCT04001829 · 2019-08-09 · 1 site observation

ACTIVE_NOT_RECRUITING

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)NCT03811002 · 2019-07-26 · 1 site observation

ACTIVE_NOT_RECRUITING

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)NCT03971474 · 2019-05-28 · 1 site observation

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT03845296 · 2019-04-16 · 1 site observation

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast CancerNCT03199885 · 2019-04-05 · 1 site observation

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung CancerNCT03793179 · 2019-04-05 · 1 site observation

ACTIVE_NOT_RECRUITING

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.